Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2020-07-09 Director's Dealing
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年06月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, supervisors, general managers, and their family members. It lists the number of shares held, changes in holdings, and other related information. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider share transactions and holdings disclosures. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2020-07-09 Chinese
109年06月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 杏輝藥品工業股份有限公司. It lists the number of shares held by directors, supervisors, and senior management, including pledged shares and shares held by spouses or minors. The document does not contain financial statements, management discussion, or any narrative typical of annual or interim reports. It is not a report of a meeting, nor a transcript or presentation. The content is focused on insider shareholdings and their changes, which aligns with the category of Director's Dealing (DIRS). The document length is 3285 characters, which is relatively short but contains substantive data on insider holdings rather than just an announcement. Therefore, the best classification is Director's Dealing (DIRS).
2020-07-09 Chinese
因本公司有價證券於集中交易市場達公布注意交易資訊標準 故公布相關財務業務等重大訊息，以利投資人區別瞭解。
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (杏輝) disclosing recent financial information due to reaching a threshold for significant trading information disclosure as per Taiwan Stock Exchange regulations. It includes recent monthly and quarterly financial data, but the data is preliminary and unaudited for the latest month. The document references compliance with disclosure rules and directs readers to the official information site for full financial reports. The document length is short (1784 characters) and it serves as a notification of financial information rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is not a certification or officer attestation, so not RNS. It is a regulatory announcement of financial information to comply with market disclosure rules, fitting the Regulatory Filings (RNS) category as a fallback for such disclosures that do not fit other categories.
2020-06-23 Chinese
109年6月19日內部人設質解質
Director's Dealing Classification · 100% confidence The document is a tabular report showing share pledge (質設) and release (解質) activities by a director or related party, including dates and share counts. It lists a director's personal share transactions related to pledging shares as collateral. The presence of director identity and share transaction details aligns with insider trading or director dealing disclosures. The document length is short and focused solely on these transactions, with no financial statements or broader company information. Therefore, it fits the definition of Director's Dealing (DIRS).
2020-06-22 Chinese
補充公告本公司參與認購子公司杏國新藥(股)公司以私募 方式辦理現金增資發行之普通股新股
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from a listed company (杏輝) regarding its participation in a private placement (private equity issuance) of common shares by its subsidiary 杏國新藥. It details the transaction specifics such as number of shares, price, total amount, relationship between parties, board approval dates, and accounting firm information. The document is short (1960 characters) and focuses on a capital transaction involving share subscription in a subsidiary. It does not contain financial statements or comprehensive financial analysis, nor is it a report or presentation. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes through private placement.
2020-06-18 Chinese
109年5月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 杏輝, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or audit information. The length is short (767 characters), and it appears to be a regulatory or public disclosure of revenue figures rather than a full financial report. There is no indication that this is an announcement of a report publication or a certification. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement of financial data without the depth of an interim or annual report.
2020-06-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.